Target intelligence / Profile preview

Lysozyme C (Gallus gallus) (HEL) (HEL)

Target
HEL
Molecular classification
Enzyme, Glycoside hydrolase, Model antigen, Lysozyme family
01

Overview

Hen Egg Lysozyme (HEL) is a 129-residue enzyme derived from Gallus gallus (chicken) that serves as a foundational model antigen in molecular immunology and drug discovery. Biologically, it is a glycoside hydrolase that catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in bacterial peptidoglycan, providing innate antibacterial defense by compromising cell wall integrity. In the pharmaceutical industry, HEL is not typically a therapeutic target for treating human disease; instead, it is used as a gold-standard 'toy' antigen for benchmarking antibody discovery platforms, such as phage and yeast display libraries, and for optimizing protein engineering tools like Rosetta. Its exceptionally well-defined crystal structure and diverse set of characterized epitopes (recognized by classic antibodies like D1.3 and HyHEL10) allow researchers to study antibody-antigen binding kinetics, affinity maturation, and paratope-epitope interactions with high precision. Furthermore, HEL is extensively utilized in transgenic mouse models (e.g., MD4 and ML5 strains) to investigate the fundamental mechanisms of B-cell tolerance, receptor signaling, and the development of B-cell malignancies like lymphoma.

Other names
Hen egg-white lysozymeChicken egg-white lysozymeMuramidaseGallus gallus lysozymeHEWL
02

Mechanism of action

Used as a model antigen to evaluate the binding affinity, specificity, and epitope binning of candidate monoclonal antibodies and CAR-T constructs in research and development settings.

03

Biological functions

Antibacterial activityPeptidoglycan hydrolysisAntigen presentationImmune response inductionInnate immunity
04

Disease associations

Used to model B-cell lymphomaUsed to model Autoimmune diseaseUsed to model Inflammatory bowel diseaseAmyloidosis (as a structural model for human LYZ)
05

Safety considerations

High immunogenicity in humans (non-self avian protein)Risk of anaphylaxis in egg-allergic individualsLimited translational utility as a human therapeutic target
06

Interacting drugs

D1.3

5 more in the full profile.

07

Biomarkers

Anti-HEL antibody titersHEL-specific T-cell proliferationHEL-peptide MHC-II complex expression

Beyond the preview

Go deeper on Lysozyme C (Gallus gallus) (HEL) (HEL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysozyme C (Gallus gallus) (HEL) (HEL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call